Skip to content

Insider · CIK 0001657494

Vincent Aurentz

director

Files at IKT (Inhibikase Therapeutics, Inc.), LBPH (Longboard Pharmaceuticals, Inc.). First filing -, latest -.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jun 30, 2025IKT
Inhibikase Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+108,176$0.00$0108,176Jul 2, 2025
Feb 21, 2025IKT
Inhibikase Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+134,427$0.00$0134,427Feb 25, 2025
Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
DDisposition to issuer
Employee Stock Option (right to buy)derivative
-12,367--0Dec 2, 2024
Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
DDisposition to issuer
Employee Stock Option (right to buy)derivative
-7,214--0Dec 2, 2024
Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
DDisposition to issuer
Employee Stock Option (right to buy)derivative
-12,367--0Dec 2, 2024
Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
DDisposition to issuer
Employee Stock Option (right to buy)derivative
-12,500--0Dec 2, 2024
Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
DDisposition to issuer
Employee Stock Option (right to buy)derivative
-22,500--0Dec 2, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Vincent Aurentz: insider trades and track record | InsiderTell